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Abstract
Non-nucleoside reverse-transcriptase inhibitor plus integrase strand transfer inhibitor–based dual therapies are an attractive
simplification, nucleoside reverse transcriptase inhibitor-sparing strategy for experienced human immunodeficiency virus-infected
patients. Thus, we performed a 24-week real-life observational study to assess efficacy and safety of switching from raltegravir plus
etravirine to dolutegravir plus rilpivirine in 7 previously heavily treated patients. This simplification strategy reduced pill burden
and preserved viral suppression in treatment-experienced patients with no major mutations to rilpivirine at historical genotyping.
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Manuscript
The introduction of a new single-tablet regimen based on
dolutegravir (DTG)/rilpivirine (RPV) has expanded the range
of nucleoside reverse transcriptase inhibitor (NRTI) sparing
options for the management of human immunodeficiency virus
(HIV)-experienced patients.1,2 For some patients, NRTI spar-
ing therapy has different advantages: avoiding NRTI-related
toxic effects and/or poor virological responses due to the
progressive accumulation of resistance mutations.3
Currently, DTG/RPV is indicated as an attractive simplifi-
cation option in patients with HIV-1 RNA <50 copies/mL and
on a stable antiretroviral regimen for at least 6 months, with no
history of treatment failure and without substitutions associated
with resistance to DTG or RPV.4
In the past, etravirine (ETR) plus raltegravir (RAL) were an
alternative NRTI sparing option, even if burdened by a daily
4 pills regimen.5,6
Rilpivirine has an improved safety and a better lipid toler-
ability, but with a lower genetic barrier compared to ETR.7-9
On the contrary, DTG has a higher genetic barrier but a lower
neuropsychiatric tolerability compared to RAL.10,11
What Do We Already Know about This Topic?
Nucleoside reverse transcriptase inhibitor (NRTI) sparing
regimens are effective in patients with VL <50 copies/mL
to avoid NRTI-related side effects.
HowDoesYourResearchContribute to the Field?
Switching from etravirine/raltegravir to rilpivirine (RPV)/
dolutegravir (DTG) is an attractive strategy both to reduce
pill burden and to preserve viral suppression in patients
with no major mutations to RPV at historical genotypic
resistance test.
What Are Your Research’s Implications toward
Theory, Practice, or Policy?
In the near future, all patients eligible to RPV/DTG dual
therapy will be able to receive a STR regimen.
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Intraclass de-escalation from ETR to RPV may successfully
reduce pill burden and preserve future options.9,11,12
In this retrospective analysis, we present a case series of 7
patients switching from ETR/RAL to RPV/DTG. We evaluated
tolerability, virological, and immunological profile and discuss
the reasons that brought to non-nucleoside reverse transcriptase
inhibitor (NNRTI)—Integrase Strand Transfer Inhibitor
(INSTI)–based regimens. All patients were in treatment with
ETR/RAL and switched to RPV/DTG; all of them were HIV-
RNA <50 copies/mL since at least 6 months, no history of RPV
or RAL failure.
The HIV-RNA, CD4 count, adherence, and any side effects
were evaluated at baseline, 4 and 24 weeks after the switch. All
data have been retrieved from electronic medical records and
no supplementary patients’ data were asked. All patients signed
informed consent at admission to our Institution for the use of
clinical data in case of retrospective observational study, and
all data were stored in the “The Ligurian HIV Clinical
network,” which has been approved by the Regione Liguria
ethical committee.13,14
Five of 7 patients were males. The mean (standard
deviation) patient age was 52.2 (13.6) years. Median year since
the diagnosis of HIV-infection was 23.4 years (range: 18-31
years). Genotypic resistance test (GRT) of protease and tran-
scriptase was available in 6 of 7 patients, NNRTI mutations are
shown in Table 1.15
Patients 1, 4, 5, and 6
These 4 patients were 50, 52, 57, and 75 years old, respectively,
who had a long history of HIV-1 infection and multiple treat-
ments with several regimens. Due to long-term treatment, few
major mutations and many thymidine analogues mutations were
accumulated over the years (Table 1), forcing to spare NRTI and
leading to the use of a NNRTI/INSTI-based regimen. Optimiza-
tion to RPV/DTG was aimed to reduce pill burden.
Patient 2
A 55-year-old male, with 20 years history of HIV-1 treatment,
did not experience any virological failures; therefore, no GRT
was performed. High cardiovascular risk and renal failure nar-
rowed the treatment options leading to the use of a NNRTI/
INSTI regimen in order to minimize side effects. Optimization
to RPV/DTG was aimed at reducing pill burden, maintaining
the advantage of a kidney-friendly regimen, thus not needing
renal adjustment in case of glomerular filtration rate decline
below 50 mL/min.
Patient 3
A 48-year-old male, with 16 years of infection, acquired HIV-1
virus with associated resistance mutations to NRTI, efavirenz,
and nevirapine with complete susceptibility to ETR. Due to its
high genetic barrier, ETR was chosen to overcome NNRTI
resistance and then replaced with RPV. Optimization to
RPV/DTG was aimed to reduce pill burden.
Patient 7
A 29-year-old female with mother-to-child transmission of
HIV-1 has a peculiar pattern of resistance, with A98G substitu-
tion, that has a debated role in conferring a low-level resistance
to RPV, thus not relevant according to IAS-USA Drug Resis-
tance Mutations Group.16 Treatment with ETV was started in
order to avoid ritonavir-related toxicity and then successfully
simplified to RPV/DTG.
Discussion
At the time of switch, the median CD4 count was 662 cells/mm3
(range: 173-989 cells/mm3). At week 4 and 24, HIV-RNA was
<50 copies/mL in all patients. After 4 weeks, the median CD4þ
T-cell count was 665 cells/mm3 (range: 173-1057 cells/mm3). At
week 24, there were no significant variations in CD4 count
(median: 602 cells/mm3, range: 230-917 cells/mm3).
The pill burden has been decreased and all patients in the
study regularly withdrew the antiretroviral therapy from our
outpatients’ service. No side effects were reported and there
were no cases of hospitalization or discontinuation in the first
24 weeks. Patient 7 confirmed virological suppression at
week 96.
Table 1. Pattern of Patients’ Mutations at Historical Genotyping.
Patient K101E/P E138K/A/G/Q/R/S L100I M230I/L Y188L Other Mutations RPV Resistance
Patient 1 No No No No No K103N, 108I, 184V No
Patient 2 NA NA NA NA NA NA NA
Patient 3 No No No No No 41L 69D 103Nw 118I 184Iw 208Y 210W 215D 215Y 219R
228R 238Tw
No
Patient 4 No No No No No K103N No
Patient 5 No No No No No M41L, K65R, M184V No
Patient 6 No No No No No K103N No
Patient 7 No No No No No A98G, P225H, K103N, D67N, T69N, K70R, M184V,
K219Q
No
Abbreviations: NA, not available; RPV, rilpivirine.
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In conclusion, switching from ETR/RAL to RPV/DTG is an
attractive strategy, both to reduce pill burden and preserve viral
suppression in treatment-experienced patients with no major
mutations to RPV at historical GRT. In the near future, all
patients included will be able to receive the new DTG/RPV-
based Single Tablet Regimen (STR).
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